The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pooled analysis of clinical outcomes with anti-PD1-based neoadjuvant immunotherapy (NeoIT) in cutaneous squamous cell carcinoma (cSCC).
 
Ines Esteves Domingues Pires da Silva
Honoraria - MSD
Consulting or Advisory Role - MSD; Regeneron; Strand Therapeutics
 
Vincent Ma
Honoraria - CAHON; Conquer Cancer, the ASCO Foundation; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Bristol Myers Squibb; Delcath Systems; General Dynamics Information Technology; Immunocore; Incyte; MDoutlook; Partner Therapeutics; Regeneron; Replimune; Targeted Oncology; Teiko.bio
Research Funding - AIQ Solutions (Inst); Astellas Pharma (Inst); C4 Therapeutics (Inst); Fujifilm (Inst); Immuneering (Inst); Immunocore (Inst); Innate Pharma (Inst); Jounce Therapeutics (Inst); Krystal Biotech (Inst); Marengo Therapeutics (Inst); Merck (Inst); Natera (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Seagen (Inst); Top Alliance BioScience (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - CAHON; Delcath Systems; Erasca, Inc; Incyte
 
Susmita Reddy Karri
No Relationships to Disclose
 
Michael Lowe
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; Merck; Regeneron; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Delcath Systems (Inst); Merck (Inst); Regeneron (Inst); Skyline Diagnostics (Inst); Vaccinex (Inst)
 
Ronen Stoff
Consulting or Advisory Role - Pangaea Biotech
Speakers' Bureau - Merck Serono; MSD Oncology
 
Andrea Boutros
No Relationships to Disclose
 
Nessr Abu Rached
No Relationships to Disclose
 
Samrin Liaqat
No Relationships to Disclose
 
Teresa Amaral
Consulting or Advisory Role - CeCaVa; Delcath Systems; Medscape; Menarini; NeraCare GmbH; Novartis; Philogen; Pierre Fabre
Research Funding - Agenus (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Biotech IOB (Inst); BMS GmbH & Co. KG (Inst); HUYA Bioscience International (Inst); Immunocore (Inst); MSD (Inst); NeraCare GmbH (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst); Skyline Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - 18/384,708 ErbB-MEL ("EGFR")
Travel, Accommodations, Expenses - NeraCare GmbH
 
Charlee Nardin
No Relationships to Disclose
 
Janice Mehnert
Stock and Other Ownership Interests - Pfizer
Honoraria - HMP; Medscape
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Sanofi/Regeneron; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); bristol myers squibb (Inst); Deciphera (Inst); GV20 Therapeutics; Incyte (Inst); Kinnate Biopharma (Inst); macrogenics (Inst); macrogenics (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Caroline Gaudy-Marqueste
Honoraria - BMS france; Pierre Fabre; UCB
Consulting or Advisory Role - Bristol Meyer Squib; Iovance Biotherapeutics; MSD Oncology; Pierre Fabre; Regeneron; Sun Pharma
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cytovation (Inst); Daiichi Sankyo Europe GmbH (Inst); Day One Biopharmaceuticals (Inst); DOT therapeutics (Inst); Dragonfly Therapeutics (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); IFX (Inst); Immunocore (Inst); Incyte (Inst); IO Biotech (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Kinnate Biopharma (Inst); Merck (Inst); Microbiotica (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Sairopa (Inst); Sotio (Inst)
Travel, Accommodations, Expenses - BMS France; MSD Oncology; Pierre Fabre
 
Eva Muñoz Couselo
Honoraria - BMS; Immunocore; MSD; Novartis; Pierre Fabre; Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Immunocore; Menarini; MSD; Novartis; Pierre Fabre; Regeneron; Sanofi
Speakers' Bureau - Bristol-Myers Squibb/Celgene; MSD; Novartis; Pierre Fabre; Sanofi
 
Christian Agbisit
No Relationships to Disclose
 
Ignasi Martim
No Relationships to Disclose
 
Lucie Heinzerling
Consulting or Advisory Role - BMS GmbH & Co. KG; Immunocore; Kyowa Kirin; MSD; Novartis; Pieris Pharmaceuticals; Sun Pharma; Therakos
Patents, Royalties, Other Intellectual Property - Eosinophilic cationic protein (ECP) as a tumor marker for malignant tumors US 17/054,217 PCT/EP2019/062378
 
Matthew Block
Research Funding - Alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Marker, Inc. (Inst); Merck (Inst); nference (Inst); Perspective Therapeutics (Inst); Pharmacyclics (Inst); Regeneron (Inst); Sorrento Therapeutics (Inst); TILT Biotherapeutics (Inst); Transgene (Inst); Viewpoint Molecular Targeting (Inst)
Patents, Royalties, Other Intellectual Property - Combinations of Dendritic Cell-Based Vaccines and Checkpoint Inhibitors, patent pending (Inst); Dendritic Cell-Based Vaccines and Uses Thereof, patent pending (Inst)
(OPTIONAL) Uncompensated Relationships - Sorrento Therapeutics; TILT Biotherapeutics; Viewpoint Molecular Targeting
 
Matteo Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; IDEAYA Biosciences; Innovent Biologics; Medison; Medison; Merck Serono; Moderna Therapeutics; MSD; Nektar; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Roche; Sanofi
 
Serigne Lo
Consulting or Advisory Role - Skyline Diagnostics
 
Karam Khaddour
No Relationships to Disclose